No description yet: the sentence for this tag has not been written. 16 records carry it: 10 people, 6 terms.
Related tags
16 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Cancer Drugs Fund (England) An NHS England fund that pays for promising cancer drugs while more evidence is collected, born in 2010 as a political fix for drugs NICE had refused and rebuilt in 2016 into a time-limited managed access scheme with a fixed budget. | none | none | law | ||
Claire Harrison Professor of Myeloproliferative Neoplasms and Clinical Director of Haematology, Guy's and St Thomas' NHS Foundation Trust · Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre Led COMFORT-II, which established ruxolitinib as the first drug for myelofibrosis, and most UK MPN trials since. | Myeloproliferative neoplasms | none | mpn, jak-inhibitor | ||
Dean A. Fennell Professor of Thoracic Medical Oncology, University of Leicester · Leicester Cancer Research Centre / University Hospitals of Leicester Led CONFIRM and MARS 2, which showed nivolumab helps relapsed mesothelioma and that radical surgery does not. | Mesothelioma | none | mesothelioma, immunotherapy, surgery | ||
Graham H. Jackson Professor of Clinical Haematology, Newcastle University; Consultant, Freeman Hospital · Newcastle Cancer Centre / Northern Centre for Cancer Care Led Myeloma XI, the 4,000-patient UK trial that proved lenalidomide maintenance extends survival after transplant. | Multiple myeloma | none | myeloma, maintenance | ||
Hisham Mehanna Professor of Head and Neck Surgery and Director, Institute of Head and Neck Studies and Education, University of Birmingham · University Hospitals Birmingham / University of Birmingham Cancer Research Centre Surgeon who led De-ESCALaTE and PET-NECK, two trials that changed how HPV-positive throat cancer is treated and followed up. | Head and neck squamous cell carcinoma | none | head-and-neck, surgery, de-escalation | ||
ILAP (Innovative Licensing and Access Pathway) The UK's post-Brexit scheme, launched in 2021 and refreshed in 2025, that brings the medicines regulator, NICE and the NHS together early in a drug's development so that licensing and the decision to pay for it can happen close together. | none | none | law | ||
Innovative Medicines Fund (England) A fund launched in 2022 that does for non-cancer medicines what the Cancer Drugs Fund does for cancer: pays for a promising but uncertain drug for a limited period while evidence is gathered, with the same budget of 340 million pounds. | none | none | law | ||
Jonathan A. Ledermann Professor of Medical Oncology, UCL Cancer Institute; Consultant, UCLH · University College London Hospitals / UCL Cancer Institute Led Study 19, the trial that first showed PARP inhibitor maintenance works in ovarian cancer. | Ovarian cancer | none | ovarian, parp | ||
Martyn E. Caplin Professor of Gastroenterology and Neuroendocrine Tumours, Royal Free Hospital and UCL · Royal Free Hospital, Royal Free London NHS Foundation Trust Led CLARINET, which showed lanreotide slows tumour growth and made somatostatin analogues first-line antiproliferative therapy for NETs. | Neuroendocrine tumours | none | neuroendocrine, somatostatin | ||
Medicines and Medical Devices Act 2021 The 2021 UK law, passed after Brexit, that gives ministers power to rewrite the rules for licensing medicines, running trials and regulating devices without new primary legislation, and that created a patient safety commissioner. | none | none | law | ||
NICE technology appraisal methods (2022) The rulebook NICE uses to decide whether the NHS in England should pay for a medicine: a cost per quality-adjusted life year usually between 20,000 and 30,000 pounds, with extra weight since 2022 for severe diseases in place of the old bonus for end-of-life cancer drugs. | none | none | law | ||
Paul Nathan Consultant Medical Oncologist, Mount Vernon Cancer Centre, London · Mount Vernon Cancer Centre Led the tebentafusp trial, the first treatment ever to extend survival in metastatic uveal melanoma. | Uveal melanoma, Melanoma | none | uveal-melanoma, bispecific | ||
Peter Hillmen Emeritus Professor of Experimental Haematology, University of Leeds · Leeds Cancer Centre, St James's University Hospital Led FLAIR, the UK trial showing MRD-guided ibrutinib plus venetoclax outperforms chemoimmunotherapy in CLL. | Chronic lymphocytic leukaemia | none | cll, mrd | ||
Rebecca C. Fitzgerald Director, Early Cancer Institute, University of Cambridge; Professor of Cancer Prevention · Cancer Research UK Cambridge Centre / CRUK Cambridge Institute Invented the Cytosponge, a swallowable sponge-on-a-string that finds Barrett's oesophagus without endoscopy. | Oesophageal cancer | none | early-detection, esophageal | ||
Serena Nik-Zainal Professor of Genomic Medicine and Bioinformatics, University of Cambridge; Honorary Consultant in Clinical Genetics · Cancer Research UK Cambridge Centre / CRUK Cambridge Institute Deciphered the mutational signatures written in cancer genomes and turned them into clinical tests like HRDetect. | Triple-negative breast cancer, HR-positive / HER2-negative breast cancer | none | genomics, mutational-signatures | ||
UK Data Protection Act 2018 and health data law The UK's data law, which keeps the EU's GDPR in domestic form and adds NHS-specific rules, so that cancer registries and research can use patient records under a public-interest basis, patients can opt out of secondary uses, and a 2025 Act loosened the consent rules for scientific research. | none | none | law |